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Abstract
Background: General transcription factor (TFII-I) is a multi-functional transcription factor encoded by the Gtf2i
gene, that has been demonstrated to regulate transcription of genes critical for development. Because of the
broad range of genes regulated by TFII-I as well as its potential role in a significant neuro-developmental disorder,
developing a comprehensive expression profile is critical to the study of this transcription factor. We sought to
define the timing and pattern of expression of TFII-I in post-implantation embryos at a time during which many
putative TFII-I target genes are expressed.
Findings: Antibodies to the N-terminus of TFII-I were used to probe embryonic mouse sections. TFII-I protein is
widely expressed in the developing embryo. TFII-I is expressed throughout the period from E8-E16. However,
within this period there are striking shifts in localization from cytoplasmic predominant to nuclear. TFII-I expression
varies in both a spatial and temporal fashion. There is extensive expression in neural precursors at E8. This
expression persists at later stages. TFII-I is expressed in developing lung, heart and gut structures. There is no
evidence of isoform specific expression. Available data regarding expression patterns at both an RNA and protein
level throughout development are also comprehensively reviewed.
Conclusions: Our immunohistochemical studies of the temporal and spatial expression patterns of TFII-I in mouse
embryonic sections are consistent with the hypothesis that hemizygous deletion of GTF2I in individuals with
Williams-Beuren Syndrome contributes to the distinct cognitive and physiological symptoms associated with the
disorder.
Background
TFII-I, or General Transcription Factor II-I (GTF2-I) is
a member of ubiquitously expressed, multifunctional
transcription factor family that integrates signals from
multiple pathways and mediates cellular response to
changes in the external environment [1]. Both the high
degree of sequence conservation in TFII-I among spe-
cies and the lack of individuals with homozygous dele-
tion of GTF2I suggest that its ubiquitous expression and
various molecular functions are essential for viability.
TFII-I gene (Entrez Gene ID 2969) has been mapped
to an interval of the human chromosome 7q11.
23 (chr7:73,805,362-73,812,956). This region is
commonly deleted in Williams-Beuren syndrome (WBS)
(OMIM#194050), which is typically associated with
hemizygous microdeletion of a 1.6 Mb region containing
about 16 genes [2-5]. In mouse, the gene (Entrez Gene
ID 14886, MGI 1202722) is located on chromosome
5qG2 (chr5:134,713,704-134,790,616). Experimentally
generated mutant mice heterozygotic for Gtf2i and for
its related transcription factor Gtf21-rd1 featured
anomalies similar to those observed in Williams-Beuren
Syndrome: retarded growth, microcephaly and craniofa-
cial and skeletal defects. Homozygous loss of Gtf2i
caused embryonic lethality [6].
Structurally, the TFII-I protein comprises several
domains that define its biological function. Additional
File 1 (Structure, Functions and Cellular Localization of
TFII-I) presents schematic diagram of TFII-I protein
structure and discusses functions of the domains. So far,
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confirmed for more than 20 genes. Additional File 2
(TFII-I Target Genes) presents a list of genes that con-
tain TFII-I binding sites in their sequences and that
were found controlled by TFII-I.
In order to expand on the available description of timing
and location of the expression of TFII-I documented in
the literature [2,7,8] we reviewed a number of resources
on gene expression profile. Additional File 3 (Develop-
mental Expression of TFII-I mRNA and Reported Expres-
sion of TFII-I in Mouse Development) summarizes
developmental expression of TFII-I mRNA based on pro-
files of expressed sequence tags (ESTs) available from
NCBI [9], data from The Jackson Laboratory on Mouse
Gene Expression Database [10,11] and EMAGE–Edin-
burgh Mouse Atlas of Gene Expression [12].
We wished to expand on the existing data regarding
expression with a focus on protein expression using
immunohistochemistry to provide spatial detail. Detailed
methods that were applied are described in Additional
File 4 (Methods).
Findings
Expression of TFII-I by developmental stage
As suggested by previous studies, TFII-I immunoreactiv-
ity is present in mouse embryo continuously from E8-
E16. The intensity, distribution and subcellular localiza-
tion vary, dependent on the stage. At E8 (Figure 1A-D),
TFII-I is expressed at higher levels in trophectodermal
derivatives rather than in the embryo. Within the
embryo TFII-I in the ectoderm is largely cytoplasmic.
Expression is also present in the mesoderm, predomi-
nantly in a cytoplasmic distribution. In contrast, at E9,
TFII-I shows discrete nuclear localization in neuroecto-
derm in addition to a more diffuse cytoplasmic distribu-
tion (Figure 2A-D and the inlet). Extensive TFII-I
immunoreactivity is also present in the eye primordium
(Figure 2B).
With increasing organ differentiation at E11, TFII-I
can be localized to a number of developing organ sys-
tems (noted in detail below).
Sections through liver (Figure 3A) show widespread,
low-level expression of TFII-I in developing hepatocytes.
This immunoreactivity is fully blocked by pre-incubation
of the antibody with peptide as described in methods
(Figure 3C, D).
The expanding lung buds at E12 (Figure 4B) express
high levels of TFII-I in the airways, vasculature and par-
enchyma. This pattern is demonstrated throughout
embryonic development (Figure 4E, C) and is discussed
in more detail below. In addition to expression in the
pulmonary system, TFII-I is highly expressed in devel-
oping heart (Figure 4A). Expression in the brain is also
noted (Figure 2E) and contrasts with that of the related
transcription factor, TFII-IRD1 (Figure 2F), as we have
previously described. TFII-I immunoreactivity is also
noted in the developing nasopharynx (Figure 2G).
A survey of tissues from E15 demonstrates expression
of TFII-I in multiple organ systems (Figures 3B, 4E, C,
5A-D). High levels of TFII-I expression are noted in
skin and hair follicles (Figure 5A) as well as in subman-
dibular glands (Figure 5B). Lung continues to show a
similar pattern of expression to earlier time points
(Figure 4E, C).
The relative expression of TFII-I in lung, diaphragm
and liver is highlighted in Figure 3B with lung and dia-
phragm showing more abundant expression than liver.
Again, immunoreactivity is eliminated by pre-incubation
of the antibody with peptide (Figure 3C, D, 4D).
Similar patterns of expression are also seen at E16.
Intense immunoreactivity is noted in skin (Figure 5C) as
well as in subcutaneous vasculature (Figure 5A, B). Gut
also demonstrates TFII-I expression, but at a lower level
(Figure 5D). Lung continues to express TFII-I in the
pattern seen at earlier stages (Figure 4C).
Expression of TFII-I by Organ Systems
As described above by developmental stage, TFII-I
expression is widespread in developing mouse embryo.
This, however, is not uniform, but instead shows varia-
tion in amount as well as sub-cellular distribution.
Further, the expression appears to follow specific
patterns based on organ system. These patterns are
summarized in the sections below.
Expression in Vasculature, Heart and Lung
TFII-I protein has been detected in adult vasculature,
endothelial cells, heart and lung. We examined the tim-
ing and localization of TFII-I in developing vascular
structures and in heart as well as in lung. Expression
was detected in vasculature beginning at E11 (data not
s h o w n ) .W ew e r eu n a b l et oi d e n t i f yv a s c u l a rs t r u c t u r e s
at earlier time points. In later time-points (Figure 4, 5),
TFII-I immunoreactivity was noted in vascular endothe-
lial cells in lung and dermis as well as in adjacent
smooth muscle cells.
Heart showed high levels of TFII-I expression begin-
ning at E11 (not shown) and throughout development
(Figure 4A). Expression was uniform throughout the
heart.
TFII-I immunoreactivity was noted throughout lung
development. Staining was most intense in the airway
epithelium early in development (Figure 4B). Later sec-
tions show staining in the adjacent vasculature as well
as in the developing air sacs (Figure 4E, C). This pattern
is also detected in adult mouse lung (not shown). The
nasopharynx, the external extreme of the respiratory
system, also expresses TFII-I from E12 (Figure 2G).
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TFII-I expression is detected in the developing gut.
Expression is most intense in the villi of the gut (Figure
5D). The liver also shows diffuse, low-level immunoreac-
tivity as early as E11 (Figure 3A). This pattern is also
noted at E15 (Figure 3B).
Expression of TFII-I in Glands and Skin
Significant TFII-I staining is noted in the skin and
glands. Beginning at E11, skin and developing hair folli-
cles show high levels of expression similar to those seen
at E15 (Figure 5A). SignificantT F I I - Ie x p r e s s i o ni sa l s o
detected in the submandibular glands as noted at E15
(Figure 5B).
Expression of TFII-I in Central Nervous System
The presence of TFII-I has been examined both in
development and adult brain because of its putative
association with Williams-Beuren Syndrome [7]. We
find that TFII-I is expressed in a regionally defined
fashion within the CNS consistent with previous reports
(Figure 1 and 2). Further, we find that TFII-I and TFII-
IRD1 demonstrate distinct patterns of expression in
embryo (Figure 2E and 2F) as observed in adult mouse.
Discussion
In early development only trace or low levels of Gtf2i
were detected between 1-cell stage and E3.5. At day
E3.5 strong signal in inner cell mass and moderate sig-
nal in trophoectoderm of blastocyst were revealed by
direct immuno-fluorescence, RT-PCR and WISH
(Whole Mount in Situ RNA Hybridization). For more
details see Additional File 3.
Our studies have identified TFII-I protein expression
in post-implantation embryos since the beginning of
organogenesis, from E8 until E16. We found that in
developmental period spanned by our study TFII-I was
continuously present in the embryo, although it’ss p a t i a l
and temporal distribution varied, as well as its sub-cellu-
lar localization (see Table 1).
Figure 1 FTFII-I expression at E8. A. Embryo and placenta (5 ×), B. Embryo at ED8, head region (16 ×), C. Placenta at ED8 (32 ×), D. Embryo,
brain region (32×). TFII-I immunoreactivity is present in both embryo and placenta at ED8. A and B. Extra-embryonic membranes demonstrate
extensive TFII-I immunoreactivity in trophectoderm (TR) derivatives, as well as in yolk sac (YS) and amniotic membrane (AM). C and D. Within the
embryo, neural ectoderm (NE) as well as mesoderm (M) shows TFII-I immunoreactivity. Of note, much of the immunoreactivity appears
cytoplasmic in localization. Abbr.: AC-Amniotic Cavity, AM-Amniotic Membrane, CS-Cardio-vascular System, D-Prospective Diencephalon, HM-
Head Mesenchyme, M-Mesoderm, NE-Neural Ectoderm, NG-Neural Groove, SE-Surface Ectoderm, TD-Trophoectoderm Derivatives, YS-Yolk Sac.
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2 (Flk1, Kdr), a receptor critical in differentiation and
angiogenesis [13,14]. In mouse development Kdr can be
detected as early as in E6.25 in embryo [15] and in E8.5
in extra-embryonic regions, in parallel to formation of
blood islands [16]. The fact that both genes are
expressed at the same time may suggest that TFII-I con-
trol over Kdr launches early in embryonic life. It was
shown recently that homozygous deletion of Gtf2i
caused embryonic lethality due to defects in yolk sac
vasculogenesis and angiogenesis: Gtf2i inactivation
resulted in downregulation of the VEGFR2, which dete-
riorated vascular signaling [6].
We found high levels of TFII-I in the airway epithe-
lium, starting at E11. This finding complements other
study which showed expression of TFII-I in the epi-
thelium and in the underlying mesenchyme during
odontogenesis in mouse embryo, between day E12.5 and
newborn [17].
O u rd a t as h o w i n gt h ep r e s e n c eo fT F I I - Ii nt h e
embryo confirm its role in cell differentiation and orga-
nogenesis, although a mechanism of its interactions is
not clear. In cultured cells TFII-I is capable of activating
the cyclin D1 gene and thus inducing transition from
phase G1 into phase S of the cell cycle [18]. Cell entry
into phase S, phase S progression and entry into phase
G2/M were significantly delayed in TFII-I knocked
down cells. It is postulated that in early phases of cell
cycle TFII-I may also control PKC-b which additionally
activates cyclin D1 via NFB pathway. TFII-I itself can
be phosphorylated by cyclin dependent kinase 1 (Cdk1)
thus amplifying phase transition signals [19].
First cyclins expressed in mouse embryo are cyclin b1
and b2, detected in the inner cell mass and the
Figure 2 TFII-I expression in head region at E9 (A-D) and at E12 (E, F, G). A. Head region (5 ×), B. Optic vesicle (32 ×), C. Neural tube (64 ×),
D. Brain region (40 ×), E-F. Brain Region (32 ×), G. Nasopharynx (40 ×). TFII-I is more discretely localized at ED9 with nuclear localization. A. At
low power, TFII-I immunoreactivity is visible in multiple regions of the embryo, but is most intense in the neural tube. B. The developing eye
demonstrates TFII-I expression in the inner and outer retinal layer as well as lens primordium. C and D. Neural tube demonstrates intense nuclear
immunoreactivity in individual cells. At E12 TFII-I is expressed extensively in brain, in contrast to TFII-IRD1, whereas TFII-I is only moderately
present in nasopharynx. E. TFII-I is expressed in both nuclear and cytoplasmic localization in brain (32 ×). F. TFII-IRD1 antibody demonstrates no
immunoreactivity in an adjacent section. G. Nasopharynx also demonstrates predominantly cytoplasmic localization (40 ×). Inset in Figure 2D
shows nuclear and cytoplasmic locatization of TFII-I under 100 × magnification (Zeiss Axioscop, obj. Apochromat 100 ×). White arrows indicate
positive reaction of specific antibody with TFII-I. Abbr.: CM-Cephalic Mesenchyme, CS-Cardiovascular System, FCC - Future Cerebral Cortex, IL-
Inner Retinal Layer, IR-Intra-Retinal Space, LP-Lens Primordium, M-Mesenchyme, NE-Neuroepithelium, NL-Neural Lumen, NT-Neural Tube, OE-
Olfactory Epithelium, OL-Outer Retinal Layer, OP-Optic Pit, PN- Primitive Nasopharynx,
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Page 4 of 8Figure 3 Liver at E11 (A, C) and at E15 (B, D). A. TFII-I is present in a principally cytoplasmic distribution in liver. B. Sections through lung (Lu),
diaphragm (Di) and liver (Li) demonstrate differential levels of TFII-I expression, with higher levels in lung and diaphragm than in liver. C and D.
Immunoreactivity is competed completely by pre-incubation of the antibody with peptide. Abbr.: Di - Diaphragm, HPC-Hepatic Primordial Cells,
Li - Liver, Lu - Lungs,
Figure 4 Heart and developing lung demonstrate TFII-I expression. A. Heart at E12 (5 ×), B. Lung at E12, C. Lung at E16, D and E. Lung at
E15. A low power view of the ED12 embryo shows extensive, largely cytoplasmic TFII-I immunoreactivity in heart. Both E12 and E16 are
representative of the pattern of TFII-I expression in lung (64 ×), showing extensive immunoreactivity in developing airway epithelium as well as
in endothelial cells lining the vasculature (arrows). Immunoreactivity is present in lung parenchyma with increased intensity and nuclear
localization at E16 compared with E12. Immuno-reactivity detected in lung at E15 (Figure 4 E) is competed completely by pre-incubation of the
antibody with peptide (Figure 4D). Abbr.: AE-Airway Epithelium, DE- Developing Epithelium, H-Heart, LB-Lobar Bronchus, PC-Pericardial Cavity, VE-
Vascular Endothelium, VS-Vascular System,
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Page 5 of 8Figure 5 Expression of TFII-I in multiple tissues at E15 and E16. A. Skin and hair follicles, B. Submandibular gland, C. Dermis (E16), D. Gut Vill
(E16), E-F. Skin and hair follicles and submandibular gland lacking immunoreactivity after pre-incubation of antibody with peptide. TFII-I
expression is present in multiple tissues at ED15 and the immunoreactivity is completely competed by cognate peptide. TFII-I is expressed in
skin and hair follicles (A) and in submandibular glands (B). Dermis demonstrates extensive immunoreactivity both in the superficial dermal layers
and in underlying mesenchyme and vessels. TFII-I immunoreactivity is prominent in nucleus as well as cytoplasm in the dermis. D. Gut villi show
both cytoplasmic and nuclear immunoreactivity particularly at the apical surface. Again, immunoreactivity is competed completely by pre-
incubation of the antibody with peptide (E-F). Inset in Figure 5D shows nuclear and cytoplasmic locatization of TFII-I under 100 × magnification
(Zeiss Axioscop, obj. Apochromat 100 ×). White arrows indicate positive reaction of specific antibody with TFII-I. Abbr.: De-Dermis, ED - Epidermis,
GV-Gut Villi, SG-Submandibular Gland, VE - Vascular Endothelium
Table 1 TFII-I expression during organogenesis, as detected by IHC. Developing organs and tissues were identified
using EMAGE gene expression database [12] and [25]
DEVELOPMENTAL STAGE ORGAN LOCALIZATION
ED8.0 Embryo,
Trophoectodermal
derivatives
Neural ectoderm, mesoderm Cytoplasmic (Fig. 1)
ED9.0 Embryo: Neural tube (brain region)
Inner and outer retinal layer
Eye primordium
Nuclear, cytoplasmic (Fig. 2)
ED11 Embryo Liver: developing hepatocytes
Vasculature: lining endothelial cells
Nasopharynx
Nuclear, cytoplasmic (Fig. 3A)
ED12 Embryo Brain
Nasopharynx
Heart
Lung buds: developing airway
epithelium, endothelial cells
Nuclear, cytoplasmic (Fig. 2E)
Cytoplasmic (Fig. 2G)
Cytoplasmic (Fig. 4A)
Nuclear, cytoplasmic (Fig. 4B, E, 4C)
ED15 Embryo Skin and hair follicles
Submandibular gland
Lung: epithelium, endothelial cells
Cytoplasmic (Fig. 5A)
Nuclear (Fig. 5B)
Nuclear, cytoplasmic (Fig. 4E)
ED16 Embryo Dermis: superficial dermal layers,
underlying mesenchyme, blood vessels
Gut: villi
Lung: airway epithelium, vascular
endothelial cells, developing alveolar
epithelium
Nuclear, cytoplasmic (Fig. 5A)
Nuclear, cytoplasmic (Fig. 5D)
Nuclear (Fig. 4C)
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Page 6 of 8trophectoderm of the blastocyst at E4.5 [20], followed by
cyclins D and E at E7.5 [21]. Again, whether such an
interaction between TFII-I and cyclins occurs at this
early development stage, remains to be revealed.
Conclusions
Based on our observations and others [2,6,8,17,22-24]
TFII-I is critical in early mouse development. The struc-
ture makes it uniquely capable of transducing multiple
regulatory signals as occurs in development. Our data
add to the existing knowledge on TFII-I function as a
pleiotropic transcription factor.
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